Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very nice info. Thanks for posting that janetcanada.
https://www104.zippyshare.com/v/uLi2Pgyw/file.html
Could you repeat that please?
$$$ LAHO
SLS R/S .. unfortunate.
https://www.streetinsider.com/dr/news.php?id=15743322&gfv=1
SURG is not surging in the right direction.
Well stated. But we know that there are multiple chat room services / groups (to many to name) and IHUB posters that are buying this for their 10% gain and move on to the the next flip .Or they'll keep flipping this while they're able. So I wouldn't be surprised to see this dip / stutter around .00418 to .00429. If it keeps its momentum after that, .007 is a target. If it blows past that, then .0119 to .0170 then a gap to .0311.
As previously stated: Looking at a 3 year Weekly chart..
The Volume for the Week was 6,609,880 when this last hit .007. It traded 216,877,532 in volume TODAY. This could easily blow past .007 IMO
Looking at a 3 year Weekly chart..
The Volume for the Week was 6,609,880 when this last hit .007. It traded 216,877,532 in volume TODAY. This could easily blow past .007
Update: 216,877,532 traded today.
The Volume for the Week was 6,609,880 when this last hit .007. It traded 216,877,532 TODAY. This could easily blow past .007 IMO.
The Volume for the week was 6,609,880 when this last hit .007 We've traded 134,197,847 so far TODAY. This could easily blow past .007 IMO.
Agreed. Another good post.
"Point is that Clay isn’t in control of anything and neither are his followers. And Clay isn’t the only person that uses the 50 mda for order placement or buy signaling. This is no secret sauce. I don’t buy this idea that he has market control. And anyone placing their buy orders on someone else’s opinion, instead of developing his/her own, has lost his/her mind. That decision should always start after personal DD and technical analysis. And the money flowing into this play is not entirely iHub nor is it Clay or Timothy Sykes or any other single person or group."
Good post. Agreed.
"What I find funny about the Clay “conspiracy theories” is that Clay has every right to trade and make money how he wants. What is most important is that it seems obvious to me that he goes out of his way to be objective when he is evaluating and analyzing a ticker’s movement. He is careful to speak from all perspectives and to largely stay neutral. If you look at his board he analyzes tons of tickers. Is he invested in all of them? Likely not. But even if he was, who cares. Listen to his analysis or don’t. At the end of the day, he isn’t telling anyone to invest or not. So I wish people would tone down the nonsense, learn to do your own analysis anyway, and stop crediting and blaming price movement on one thing or person."
One of the best posts on this board. Eloquent, truthful, insightful.
"It is always tough to gauge an expected PPS because of all the factors involved. I would tend to think of each layer of the PR onion to be worth a penny here. If they roll out great numbers, then probably .03 to .05 is realistic. Seen it in many pennies with similar share structures. What could drive this past a nickel is the huge amount of interest coupled with the fact that they are both international and possess a large stem cell footprint. As I have said before, they are almost a perfect OTCBB uplist and/or buyout candidate down the road.
The cautionary note is this - all of these companies use the OTC pinks to raise capital first and they tend to ignore common shareholder interests later (once they get what they want). This is the reason why you have more traders than investors here. With that in mind, holding for a quarter is too hard for most traders and they will take profits after each penny mark is reached. Therefore, getting to a quarter with this share structure would be nearly impossible; however, a dime would not be outside the realm of possibility. In my opinion."
Thanks LiveLife. 2/5 is interesting. I see what you're saying.
Does the 5 always have to cross over the 30 for you or do you ever consider a buy when the Price crosses over the 5 SMA?
TTOO is having a pretty good run. Looked at it with your 5/30 SMA chart settings. I'm not in it. I was and sold way too early. I've been using an 8/34 EMA setting when looking at bottom plays. Pretty similar I think. I set up a 5/30 chart on my stockcharts.com
I'm glad I found this board. Really like it. Funny, I use the same Finviz set up for most of my scans. Sometimes I narrow it down with percentage up. I like the educational part of your board too. kudos.
Cool. I like a little better Avg Vol too. This looks good to me though.
Take a look at PDS for a potential move higher. Looking at 1.38 /1.47.
Like your watch List
Sorry. Wrong Link
https://finance.yahoo.com/news/yangtze-river-port-logistics-limited-183000547.html
NEW YORK, Aug. 28, 2019 /PRNewswire/ -- On January 23, 2019, Yangtze River Port and Logistics Limited (YRIV) (the "Company") filed a defamation lawsuit in the New York Supreme Court, New York County, against Hindenburg Research, Nathan Anderson, ClaritySpring Securities LLC and ClaritySpring Inc. (collectively, "Defendants") in response to their coordinated and orchestrated market manipulation scheme to disseminate false, misleading, and defamatory content to the marketplace regarding the Company for the purpose of inflicting substantial reputational harm on the Company for Defendants' own financial gain. The details and updates regarding the lawsuit are as follows:
1. The Company Established a Special Committee for Internal Investigation
A week after HR published its Report on the Company, the Company established a special committee (the "Special Committee") composed of independent directors to carry out a special internal investigation, for the purpose of investigating each allegation published in HR's Report. The Company took into consideration that HR's Report mainly referred to the Company's subsidiary in Wuhan, China, and its projects. The Special Committee consisted of the Company's personnel in China, led primarily by independent directors Mr. Zhihong Su, Mr. Tongmin Wang, and Mr. Zhixue Liu. Mr. Zhihong Su is an independent director of the Company and also a member of the Company's Audit Committee and the Chairman of the Governance and Human Resources Committee under the Company's Board of Directors. Since December 2001, Mr. Su has also been a managing partner of Beijing Hengjun Law Firm, a law firm that provides services in securities, business, and litigation, and is also familiar with corporate and banking law. Mr. Tongmin Wang is an independent director of the Company and a member of the Company's Audit Committee. Mr. Zhixue Liu is an independent director of the Company and a member of the Board of Supervisors Committee. The Special Committee's review included, but was not limited to, reviewing the relevant financial records, public documents, lease agreements, and court documents of the Company's Wuhan subsidiary.
2. Filing of Lawsuit against HR and Related Personnel Based on the Findings and Proposals of the Company's Special Committee
Upon conclusion of the investigation, Mr. Zhihong Su, Mr. Tongmin Wang, and Mr. Zhixue Liu orally presented the Special Committee's investigations to the Company's Board of Directors, and proposed to file a lawsuit against HR. The Company then proceeded to file a defamation lawsuit against the Defendants on January 23, 2019, which the Company correspondingly announced through its January 24, 2019 8-K filing.
3. The Special Committee's Findings and Details Regarding the Complaint
In the Complaint, the Company systematically enumerated and refuted the errors contained in the Report, and pled the following causes of action against HR and related personnel (collectively, the "Defendants"): (i) defamation per se, (ii) defamation, (iii) tortious interference with prospective business relations, (iv) tortious interference with contract, (v) civil conspiracy, and (vi) common law fraud. The Company also claimed that after creating one or more "short" positions in the Company's stock, Defendants conspired to publish, publicize, and disseminate its erroneous Report in order to jointly manipulate and depress the Company's stock price. After publishing the false report, Defendants republished and directed online "traffic" through one or more websites and social media accounts to the Report, which was replete with false, misleading, and defamatory statements. Additional information regarding the Special Committee's findings can be found in the Complaint, available online on the New York State Unified Court System's website:
https://iapps.courts.state.ny.us/fbem/DocumentDisplayServlet?documentId=3hZXjsLXc_PLUS_DKCyi0KWoJyQ==&system=prod
4. Litigation Progress
The Lawsuit against HR continues to proceed in the Supreme Court of New York. Defendants filed a Motion to Dismiss Complaint, and oral arguments for the same motion was originally scheduled for August 14, 2019, but the Court adjourned the hearing until October 7, 2019.
After the Report was released, the Company's market capitalization was reduced by nearly $2 billion, which caused huge losses to all of the Company's shareholders. Management believes that the Company will prevail in this lawsuit, and any resolution will not have a material adverse effect on the financial condition or results of operations of the Company.
CONTACT:
James Coleman
Executive Director
jcoleman@yerr.com.cn
646-861-3315
After the Report was released, the Company's market capitalization was reduced by nearly $2 billion, which caused huge losses to all of the Company's shareholders. Management believes that the Company will prevail in this lawsuit, and any resolution will not have a material adverse effect on the financial condition or results of operations of the Company.
https://finance.yahoo.com/m/9fcf94ca-5d57-3465-aa10-de029a0b52cc/ss_how-much-are-yangtze-river.html
LINK ?
Poor shorts yriv filed appeal to be relisted on the nasdaq see you then :)
Nice Post. Hopefully they will start using Warp Core Dilithium Crystals in their process. That will churn things up.
Go SHMP
Nice 4th Quarter. It's a shame for the drop today.
https://finance.yahoo.com/news/hometrust-bancshares-inc-reports-fourth-130000277.html
ASHEVILLE, N.C., July 25, 2019 (GLOBE NEWSWIRE) -- HomeTrust Bancshares, Inc. (HTBI) ("Company"), the holding company of HomeTrust Bank ("Bank"), today announced preliminary net income increased 11.2% to $8.0 million, or $0.44 per diluted share for the fourth quarter of fiscal 2019, compared to $7.2 million, or $0.38 per diluted share for the same period a year ago. Net income totaled $27.1 million, or $1.46 per diluted share for the year ended June 30, 2019, compared to $8.2 million, or $0.44 per diluted share for fiscal year 2018. Earnings during the year ended June 30, 2019 were negatively impacted by a $5.7 million provision primarily related to one $6.0 million commercial lending relationship, which was fully charged off. Earnings for the year ended June 30, 2018 included a $17.9 million write-down of deferred tax assets following a deferred tax revaluation resulting from enactment of the Tax Cuts and Jobs Act (“Tax Act”) with no comparable charge in fiscal year 2019.
"We concluded fiscal 2019 on yet another high note set by record net income,” said Dana Stonestreet, Chairman, President and Chief Executive Officer. “Our success reflects the hard work of our employees to ensure our customers and communities are, as we like to say, Ready for What's Next. As a result, we had over $1 billion in loan originations for the second year in a row; net organic loan growth of 10%; SBA loan sales that generated $3.4 million in noninterest income; and our new equipment finance line of business originated $147 million in loans and leases during the year. Continued improvements in our financial performance led to our first cash dividend along with the adoption of our sixth stock repurchase program. As we look into fiscal 2020 and beyond, we will remain focused and disciplined on executing our strategic plan to deliver more value to our customers and shareholders."
Highlights for the quarter ended June 30, 2019 compared to the corresponding quarter in the previous year:
return on assets ("ROA") increased 4.5% to 0.92% from 0.88%;
net interest income increased $1.0 million, or 3.9% to $26.9 million from $25.9 million;
noninterest income increased $1.7 million, or 34.6% to $6.8 million from $5.1 million;
provision for loan losses increased to $200,000 from $0;
organic net loan growth, which excludes purchases of home equity lines of credit, was $56.0 million, or 8.9% annualized compared to $80.3 million, or 14.1% annualized;
292,630 shares were repurchased during the quarter at an average price of $25.01 per share; and
quarterly cash dividends of $0.06 per share totaling $1.1 million.
Highlights for the year ended June 30, 2019 compared to the year ended June 30, 2018:
ROA was 0.80%, compared to 0.25%;
net interest income increased $5.5 million, or 5.5% to $106.9 million from $101.3 million;
noninterest income increased $3.9 million, or 20.7% to $22.9 million from $19.0 million;
provision for loan losses increased to $5.7 million from $0;
net loans receivable increased 7.1% to $2.7 billion from $2.5 billion;
organic net loan growth was $228.6 million, or 9.7% compared to $171.3 million, or 7.8%;
nonperforming assets decreased 9.0% to $13.3 million, or 0.38% of total assets compared to $14.6 million, or 0.44% of total assets;
total deposits increased 6.0% to $2.3 billion from $2.2 billion; and
1,149,785 shares of common stock were repurchased during the year at an average price of $26.65 per share.
This should be an interesting day between investors & flippers.
CODX News
[url][/url][tag]https://finance.yahoo.com/news/co-diagnostics-inc-coprimers-high-103000250.html[/tag]
Salt Lake City, UT, July 18, 2019 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today favorable results of a study to detect cancer mutations using its patented CoPrimer™ technology, with applications in liquid biopsy and companion diagnostic tests.
Unlike invasive and more expensive tissue biopsies, liquid biopsies identify traces of cancer in a simple blood draw. The Company's study, performed on circulating free DNA (cfDNA) reference materials, demonstrated highly specific detection of the ten mutations associated with non-small cell lung cancer (NSCLC), reliably and successfully distinguishing the genes with mutations from those without. The CoPrimer-based polymerase chain reaction (PCR) test was also shown to be highly sensitive, identifying the NSCLC genes at the lowest possible percentage available with the reference material.
PCR-based liquid biopsy tests are simpler and more affordable compared to other methods of monitoring cancer patients, such as whole-body imaging, although relatively few blood tests are currently available. The results of the Company's study also confirm the usefulness of the CoPrimer platform as a cancer treatment companion diagnostic, to monitor treatment response and provide early detection of drug resistance mutations.
Dwight Egan, Co-Diagnostics CEO, commented: "The global cancer diagnostics market was recently valued at $144 bn and growing, as healthcare professionals focus on more effective diagnostics and monitoring to battle one of the leading causes of death worldwide. We anticipate a large and ready market among clinical laboratories for NSCLC and other cancer liquid biopsy tests designed on our CoPrimer platform. Given the relatively few PCR liquid biopsy tests on the market and the growing demand for more, we believe the advantages of our technology will create meaningful revenue opportunities and position Co-Diagnostics to become a leading innovator of liquid biopsy solutions.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.[url][/url][tag]insert-text-here[/tag]
Best of luck on this.
All the best to you MadHatter.
Looks like you'll be able to get a bunch more under .40 soon.
Does anyone here have an idea of how many people have lost money in penny stocks because they had special connections or conversations with the CEO of the penny stock telling them about their big plans? If you're trading the Story, good luck. If you're trading the Chart .. not looking to hot in my opinion.
6 Months. Marking your post.
Wow. That's A lot of money waved good bye to over the last 2 months.
Looks to me like some of these "dedicated Longs" are trying to scale out of this one.
Nice Chart!
Very eloquent and insightful.
Don't see the post you said was coming. Maybe Clay and his buddies aren't interested in shorting a penny stock.
FB Post. Is there a Link you could provide? I could not find this on FB. Could be user error on my part.
Peter 5 minutes ago on facebook: I have all of you in mind and think about you guys every 18 hour day that I spend on the road to make this company a realization for all of us. There are no issues inside the company and if I do post positive updates as information provided to you as a private company representing a joint interest into a public company I am accused of fluff. If I don't post updates I am then accused of withholding information that must mean doom and gloom for the company. So I choose to POST AGAIN as I have no doubts of our futute in aquaculture as a contributor to this market. I wish you all coud see what I see, know what I know and feel the impact of being a disruptor of traditional market capabilites. Believe me or not I haven't had a day off since the Aquaculture 2019 show and have been on a customer location all week solving issues affecting fellow farmers in our space. As a matter of fact, as of last night, every single company I personally met with is working with us at one stage or another. It has been a beautiful experience to behold understanding that the impacts may not be presented yet in a public forum. What I can tell you is we are real, our solutions are being adopted and progress and announcements are inevitable whether this week or next. I involve myself out of unmanufactured emotion as i do not know anyone who actually knows me that would think I woud ever leave a man or woman behind knowing you have placed your "Faith and Trust" in me and us. For those this message can not connect with I understand and accept the fact that in a quick hit society immediate gratification is required. My message is to the group of you who got into SHMP because the world needs our contribution, vison and execution of a global aquaculture capability and all that goes with doing the hard work, spending the time at the helm and creating something uniquely atractive in a sea of noise. To all our fellow shrimpers out there I am here for your service and will represent you to the best of my capability for all those who choose to stay the course and on board I will help fulfill our joint destiny believe it or not. We are truly Copper Bottomed.
Seems what NS is trying to accomplish is an answer/solution to the problems highlighted in this report. Really good report. Thanks for sharing.
We test imported shrimp bought from supermarket chains across the country. While it's expected we'll find bacteria on raw shrimp, how many of those common bugs are resistant to antibiotics? Experts claim antibiotic resistance poses the biggest threat to modern medicine in the 21st century, so is the government doing enough to stop these superbugs from ending up in our kitchens?
Testing shrimp for antibiotic-resistant bacteria (Marketplace)
Will go down in history
as the biggest P&D since spongetech
The party has been over here except for those shorting.